• Save
Hypertension and Drug Dose Monitoring - Business Plan
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Hypertension and Drug Dose Monitoring - Business Plan

  • 271 views
Uploaded on

This is our final presentation of Summer School at High Tech Campus, Eindhoven, about our product DrugArt's business plan. We won the Best Entrepreneurial Team, at EIT ICT Labs Summer School,......

This is our final presentation of Summer School at High Tech Campus, Eindhoven, about our product DrugArt's business plan. We won the Best Entrepreneurial Team, at EIT ICT Labs Summer School, Wellbeing Innovation Camp 2013.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
271
On Slideshare
215
From Embeds
56
Number of Embeds
2

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 56

http://rosejay.org 51
https://www.linkedin.com 5

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. EITeam4 Hypertension & Drug Dose Monitoring
  • 2. 1.000.000.000 Hypertension Patients 350.000.000 Overdosed 9.400.000 Deaths 10.000.000.000 € Annual Savings Problems
  • 3. Patients Doctors Pharma Companies Insurance Companies Decision Makers
  • 4. Over Dosage Timing of Dosage Reliable & 24/7 Monitoring Reliability of Intake It may be possible to reduce the number and dosage of drugs. “ ESH/ESC Guidelines for the management of arterial hypertension, 2013 10 Billion ProblemsMarket(€) Decision Makers Targeted Problems Ineffectivity of Drugs
  • 5. Over Dosage Timing of Dosage Reliability of Intake Reliable & 24/7 Monitoring 10 Billion 70 Million ProblemsMarket(€) Targeted Problems Decision Makers Ineffectivity of Drugs
  • 6. Over Dosage Timing of Dosage Reliability of Intake “ The importance of adequate BP control over the entire 24-hour period. Journal of Managed Care Pharmacy, William B. White 2007 Reliable & 24/7 Monitoring 10 Billion 70 Million 1.5 Billion ProblemsMarket(€) Targeted Problems Decision Makers Ineffectivity of Drugs
  • 7. Over Dosage Timing of Dosage Reliability of Intake More than 50% of all medicines are prescribed, dispensed or sold inappropriately May 2010, WHO “ 10 Billion 70 Million 1.5 Billion 5 Billion Reliable & 24/7 Monitoring ProblemsMarket(€) Targeted Problems Decision Makers Ineffectivity of Drugs
  • 8. Over Dosage Timing of Dosage Ineffectivity of Drugs Reliability of Intake Half of all patients fail to take medicines correctly. May 2010, WHO “ 10 Billion 70 Million 1.5 Billion 5 Billion 2 Billion Reliable & 24/7 Monitoring ProblemsMarket(€) Targeted Problems Decision Makers
  • 9. Clinical Platform 1 2 Optimal Dose Intake Monitoring Blood Pressure Heart Beat Rate Drug Dose Info Physical Exercise Value Proposition
  • 10. Strategy
  • 11. Clinics End User Care Cardiologists Publications ISH WHO ASH ESH Strategy
  • 12. Clinics End User Care Cardiologists Publications ISH WHO ASH ESH Strategy Insurance Companies (Joint Insurance) Allianz Aetna AXA PPP
  • 13. Clinics End User Care Cardiologists Publications ISH WHO ASH ESH Strategy Pharma Companies Bayer Teva Novartis Merck & Co. Insurance Companies (Joint Insurance) Allianz Aetna AXA PPP
  • 14. Clinics End User Care Cardiologists Publications ISH WHO ASH ESH Strategy Pharma Companies Bayer Teva Novartis Merck & Co. Insurance Companies (Joint Insurance) Allianz Aetna AXA PPP GP End User Prevention
  • 15. Clinics End User Care GP Insurance Companies (Joint Insurance) Pharma Companies Cardiologists End User Prevention Revenue Streams Worldwide
  • 16. Clinics End User Care GP Insurance Companies (Joint Insurance) Pharma Companies Cardiologists End User Prevention 1 Revenue Streams Worldwide
  • 17. Clinics End User Care GP Insurance Companies (Joint Insurance) Pharma Companies Cardiologists End User Prevention 1 Revenue Streams 2 Worldwide
  • 18. Clinics End User Care GP Insurance Companies (Joint Insurance) Pharma Companies Cardiologists End User Prevention 1 3 Revenue Streams 2 Worldwide
  • 19. Go to India
  • 20. 1.2 billion population Go to India
  • 21. 1.2 billion population 40 million potential customers Go to India
  • 22. 1.2 billion population 40 million potential customers 10% penetration in 10 years Go to India
  • 23. 1.2 billion population 40 million potential customers 10% penetration in 10 years Go to India Hypertension is a well-known chronic disease
  • 24. Clinics End User Care GP Pharma Companies Cardiologists 1 3 Go to India 2
  • 25. -30 65 160 255 350 Roadmap & Financials 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Operating Profit Cumulative Operating Profit million € 0 Cumulative Operating Profit with Pharmas ROI
  • 26. Risk Analysis 0 25 50 75 100 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Technical Value Proposition Competition Go 2 Market
  • 27. Costs 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 R&D 3000000 2000000 1000000 1000000 500000 500000 250000 250000 250000 250000 250000 Patenting 100000 100000 100000 0 0 0 0 0 0 0 0 Marketing & Market research 2000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 5000000 Platform running cost 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 Salaries 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 1000000 Logistics 50000 100000 100000 100000 100000 100000 100000 100000 100000 100000 100000 Misc Market Penetration Cost 5000000 10000000 10000000 10000000 25000000 25000000 10000000 10000000 10000000 10000000 10000000 Cost Breakdown
  • 28. Nurse Visiting Hospital Visiting Clinical Cost Data Security Privacy Drug Coverage Side Effects Connection Report Life Style Service Cost Our Product Proteus Traditional high low Competition